Omer Goldman

Omer Goldman

Auto-generated profile, based on publicly available information

Omer Goldman

Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2023 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
OGOmer Goldman
Omer Goldman
LALital N. Adler
Lital N. Adler
EHEmma Hajaj
Emma Hajaj
TCTommaso Croese
Tommaso Croese
NDNaama Darzi
Naama Darzi
AEAyelet Erez
Ayelet Erez
Multiple studies have identified metabolic changes within the tumor and its microenvironment during carcinogenesis. Yet, the mechanisms by which tumors affect the host metabolism are unclear. We find that systemic inflammation induced by cancer leads to liver infiltration of myeloid cells at early extrahepatic carcinogenesis. The infiltrating immune cells via IL6–pSTAT3 immune–hepatocyte cross-talk cause the depletion of a master metabolic regulator, HNF4α, consequently leading to systemic metabolic changes that promote breast and pancreatic cancer proliferation and a worse outcome. Preserving HNF4α levels maintains liver metabolism and restricts carcinogenesis. Standard liver biochemical tests can identify early metabolic changes and predict patients’ outcomes and weight loss. Thus, the tumor induces early metabolic changes in its macroenvironment with diagnostic and potentially therapeutic implications for the host. Significance: Cancer growth requires a permanent nutrient supply starting from early disease stages. We find that the tumor extends its effect to the host's liver to obtain nutrients and rewires the systemic and tissue-specific metabolism early during carcinogenesis. Preserving liver metabolism restricts tumor growth and improves cancer outcomes. This article is highlighted in the In This Issue feature, p. 1501

16 September 2024
Verified
Other
Open access
PDF file
OGOmer Goldman
Omer Goldman
LALital N. Adler
Lital N. Adler
EHEmma Hajaj
Emma Hajaj
TCTommaso Croese
Tommaso Croese
NDNaama Darzi
Naama Darzi
AEAyelet Erez
Ayelet Erez
Supplementary Table S5 lists the antibodies used for CyTOF

16 September 2024
Verified
Other
Open access
PDF file
OGOmer Goldman
Omer Goldman
LALital N. Adler
Lital N. Adler
EHEmma Hajaj
Emma Hajaj
TCTommaso Croese
Tommaso Croese
NDNaama Darzi
Naama Darzi
AEAyelet Erez
Ayelet Erez
Supplementary Table S2 lists the antibodies used for western blots

16 September 2024
Verified
Other
Open access
PDF file
OGOmer Goldman
Omer Goldman
LALital N. Adler
Lital N. Adler
EHEmma Hajaj
Emma Hajaj
TCTommaso Croese
Tommaso Croese
NDNaama Darzi
Naama Darzi
AEAyelet Erez
Ayelet Erez
Supplementary Table S4 lists the antibodies used for FACS

16 September 2024
Verified
Other
Open access
PDF file
OGOmer Goldman
Omer Goldman
LALital N. Adler
Lital N. Adler
EHEmma Hajaj
Emma Hajaj
TCTommaso Croese
Tommaso Croese
NDNaama Darzi
Naama Darzi
AEAyelet Erez
Ayelet Erez
Supplementary Figure S2 demonstrates the infiltration of mature innate immune cells to the liver during breast carcinogenesis

26 June 2023
Verified
Other
Open access
PDF file
OGOmer Goldman
Omer Goldman
LALital N. Adler
Lital N. Adler
EHEmma Hajaj
Emma Hajaj
TCTommaso Croese
Tommaso Croese
NDNaama Darzi
Naama Darzi
AEAyelet Erez
Ayelet Erez
Supplementary Figure S1 demonstrates global metabolic changes in liver metabolism during early BC carcinogenesis